Sinomab Bioscience Ltd.

The dynamics of the cutaneous lupus erythematosus market are anticipated to change in the coming years owing to the expected launch of emerging therapies. The rising research and prevalence, along with the emergence of novel therapies, will fuel the cutaneous lupus erythematosus market during the forecast period of 2023–2032. LAS VEGAS, Aug. 29, 2023 /PRNewswire/ -- DelveInsight's Cutaneous Lupus Erythematosus Market Insights report includes a comprehensive understanding of current treatment practices, cutaneous lupus erythematosus emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan] and China. Key Takeaways from the Cutaneous Lupus Erythematosus Market Report As per DelveInsight analysis, the cutaneous lupus erythematosus market size in the 7MM and China was approximately USD 580 million in 2022 and it is expected to grow positively at a significant CAGR during the study period (2019–2032). As per the DelveInsight estimates, in 2022, the total diagnosed prevalent cases of cutaneous lupus erythematosus were around 1.4 million cases in the 7MM and China, which are expected to grow during the study period, i.e., 2019-2032. Globally, leading cutaneous lupus erythematosus companies such as Biogen, Horizon Therapeutics, Bristol-Myers Squibb, Gilead Sciences, Daiichi Sankyo, Inc., EMD Serono, Hoth Therapeutics, Zylo Therapeutics, Sanofi, Merck KGaA, Kyowa Kirin Co., Ltd., Priothera Ltd., Centessa Pharmaceuticals, Horizon Therapeutics, and others are developing novel cutaneous lupus erythematosus drugs that can be available in the cutaneous lupus erythematosus market in the coming years. Some key therapies for cutaneous lupus erythematosus treatment include Litifilimab, Daxdilimab, SOTYKTU (deucravacitinib), Edecesertib, DS-7011a, Enpatoran , and others. Discover which therapies are expected to grab the major cutaneous lupus erythematosus market share @ Cutaneous Lupus Erythematosus Market Report Cutaneous Lupus Erythematosus Overview Cutaneous lupus erythematosus (CLE) is a subtype of lupus erythematosus, an autoimmune disorder that primarily affects the skin. Cutaneous lupus erythematosus specifically targets the skin, causing a range of distinctive symptoms and manifestations. The exact cause of CLE is not fully understood, but it is believed to result from a complex interplay of genetic predisposition, environmental triggers, and immune system dysfunction. Cutaneous lupus erythematosus symptoms can vary widely and often depend on the specific subtype, which includes discoid lupus erythematosus (DLE), subacute cutaneous lupus erythematosus (SCLE), and tumid lupus erythematosus (TLE). Common symptoms include skin rashes, lesions, and sensitivity to sunlight. The characteristic butterfly-shaped rash across the cheeks and nose, known as malar rash, is often associated with lupus. Diagnosing cutaneous lupus erythematosus involves a combination of clinical evaluation, medical history assessment, and laboratory tests. Dermatologists and rheumatologists may collaborate in the diagnostic process. Skin biopsies of affected areas can reveal specific histopathological features that help differentiate CLE from other skin conditions. Blood tests, such as antinuclear antibody (ANA) testing, can also assist in confirming the diagnosis and ruling out systemic involvement. Cutaneous Lupus Erythematosus Epidemiology Segmentation As per the DelveInsight estimates, in 2022, the total tumor prevalent cases of CLE by gender were around 347K and 1.1 million cases for males and females, respectively, in the 7MM and China, which are expected to grow during the study period, i.e., 2019─2032. The cutaneous lupus erythematosus market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM and China segmented into: Total Diagnosed Prevalent Cases Total Prevalent Cases of CLE by Gender Total Prevalent Cases of CLE by Type Total Treated Cases Total Prevalent Cases of CLE by Severity Cutaneous Lupus Erythematosus Treatment Market Cutaneous lupus erythematosus treatment is a nuanced process that takes into account the diverse clinical presentations and underlying immune mechanisms of the disorder. For patients with mild, localized forms of CLE, topical therapies like corticosteroid creams, calcineurin inhibitors, and retinoids can be beneficial in reducing inflammation and controlling symptoms. Antimalarial medications, such as hydroxychloroquine, are considered a cornerstone of CLE treatment due to their ability to modulate the immune response and mitigate skin manifestations. In cases of more extensive or persistent CLE, systemic treatments may be necessary. Immunosuppressive drugs like methotrexate, azathioprine, mycophenolate mofetil, and cyclosporine can help manage the immune dysfunction that triggers skin symptoms. Biologic agents, which target specific components of the immune system, are emerging as potential options for severe or treatment-resistant cases. However, the cutaneous lupus erythematosus treatment landscape is complex and evolving. Therapeutic choices are tailored to the individual's subtype, symptom severity, and overall health. Additionally, patient education on sun protection and skin care remains a crucial aspect of CLE management, as ultraviolet light can exacerbate symptoms. Multidisciplinary collaboration between dermatologists, rheumatologists, and other healthcare providers ensures a comprehensive approach to care, addressing not only the physical symptoms but also the psychological and emotional aspects of living with a chronic autoimmune condition like CLE. Regular monitoring and adjustment of treatment plans, along with ongoing research efforts, contribute to refining the strategies for managing cutaneous lupus erythematosus. To know more about cutaneous lupus erythematosus treatment, visit @ Cutaneous Lupus Erythematosus Treatment Drugs Key Cutaneous Lupus Erythematosus Therapies and Companies Litifilimab: Biogen Daxdilimab: Horizon Therapeutics SOTYKTU (deucravacitinib): Bristol-Myers Squibb Edecesertib: Gilead Sciences DS-7011a: Daiichi Sankyo, Inc. Enpatoran: EMD Serono Learn more about the FDA-approved drugs for cutaneous lupus erythematosus @ Drugs for Cutaneous Lupus Erythematosus Treatment Cutaneous Lupus Erythematosus Market Dynamics The cutaneous lupus erythematosus market dynamics have undergone a significant transformation in recent times. This relatively understudied facet of lupus, primarily affecting the skin, has gained recognition due to heightened awareness and improved diagnostic techniques. The growing prevalence of autoimmune disorders, including CLE, has prompted pharmaceutical companies to invest in research and development endeavors targeting innovative treatment approaches. Clinicians and patients alike are advocating for therapies that not only alleviate the visible symptoms of skin involvement but also address the underlying immune dysregulation. The advent of precision medicine has fueled the exploration of targeted interventions, such as monoclonal antibodies and Janus kinase (JAK) inhibitors, tailored to counteract specific immune pathways driving CLE. These advancements, although promising, come with challenges like high development costs and the need for comprehensive clinical trials to establish efficacy and safety profiles. Additionally, the cutaneous lupus erythematosus market dynamics are influenced by the demand for non-pharmacological interventions, such as photoprotective measures and lifestyle modifications, which form an integral part of holistic CLE management. Despite increased attention, the limited understanding of CLE's intricate pathophysiology remains a significant hurdle. The complexity of immune system dysregulation specific to skin involvement presents challenges in identifying suitable drug targets and developing precise interventions. Additionally, the lack of standardized diagnostic criteria for various CLE subtypes can delay accurate diagnosis and initiation of appropriate treatment. Limited awareness and knowledge among healthcare professionals regarding CLE's diverse manifestations can lead to misdiagnosis or underdiagnosis, affecting patient access to timely and proper care. This is exacerbated by the scarcity of dedicated treatment guidelines, leading to variations in therapeutic approaches. Moreover, as the cutaneous lupus erythematosus market moves towards personalized medicine, the challenge of developing treatments that can cater to the genetic and immunological diversity of CLE patients becomes evident. Scope of the Cutaneous Lupus Erythematosus Market Report Therapeutic Assessment: Cutaneous Lupus Erythematosus current marketed and emerging therapies Cutaneous Lupus Erythematosus Market Dynamics: Conjoint Analysis of Emerging Cutaneous Lupus Erythematosus Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Cutaneous Lupus Erythematosus Market Access and Reimbursement Discover more about cutaneous lupus erythematosus drugs in development @ Cutaneous Lupus Erythematosus Clinical Trials Table of Contents Related Reports Cutaneous Lupus Erythematosus Pipeline Cutaneous Lupus Erythematosus Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key cutaneous lupus erythematosus companies, including Hoth Therapeutics, Zylo Therapeutics, Sanofi, Gilead Sciences, Bristol-Myers Squibb, Merck KGaA, Kyowa Kirin Co., Ltd., Priothera Ltd., Centessa Pharmaceuticals, Horizon Therapeutics, among others. Cutaneous Lupus Erythematosus Epidemiology Cutaneous Lupus Erythematosus Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted cutaneous lupus erythematosus epidemiology in the 7MM. Systemic Lupus Erythematosus Market Systemic Lupus Erythematosus Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key systemic lupus erythematosus companies, including GlaxoSmithKline, AstraZeneca, Eli Lilly and Company, Biogen, UCB Pharma, Biogen, Immupharma, Hoffmann-La Roche, Xencor, Idorsia Pharmaceuticals, Bristol-Myers Squibb (Celgene), Resolve Therapeutics, Genentech (Roche), Pfizer, among others. Systemic Lupus Erythematosus Pipeline Systemic Lupus Erythematosus Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myasthenia gravis companies, including Yake Biotechnology, UCB, Sorrento Therapeutics, SinoMab Bioscience Ltd, Shanghai Junshi Biosciences, Sareum, Sanofi, Roche, Rheos Medicine, Resolve, Provention Bio, Pfizer, Novartis, Neovacs, Merck, Medsenic, Landos Biopharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, Janssen Research & Development, Janssen, InnoCare, ImmuPharma, I-MAB Biopharma, ILTOO, Idorsia Pharmaceuticals, Horizon Therapeutics, Genovax, Exinda Thearapeutics, Equillium, Eli Lilly and Company, Eisai, Daiichi Sankyo Company, Corestem, Corbus Pharmaceuticals, Citryll BV, Chipscreen Biosciences, Carna Bioscience, Bristol-Myers Squibb, Brickell Biotech, Boston Pharmaceuticals, Biogen, Athos Therapeutics, Asahi Kasei Pharma, Aria Pharmaceuticals, Antengene Therapeutics, Amgen, Alpine Immune Sciences, Akeso Biopharma, AbbVie, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

SHANGHAI, Sept. 25, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced today that the China National Medical Products Administration (NMPA)'s Center for Drug Evaluation has approved the Investigational New Drug (IND) application for a Phase 1b study of EVER001 (previously known as XNW1011), a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor, in development for the treatment of glomerular diseases. The planned Phase 1b clinical study will evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of EVER001 in patients in China with glomerular disease characterized by proteinuria, a common cause of chronic kidney disease. Under an exclusive licensing agreement with Sinovent Pharmaceuticals and SinoMab BioScience in September 2021, Everest owns the global rights to develop, produce and commercialize EVER001 for the treatment of renal diseases. Based on a Phase 1 study in healthy subjects in China conducted by SinoMab, EVER001 exhibited high selectivity, excellent pharmacokinetics properties and safety profile as well as robust target engagement. "The advancement in clinical development of EVER001 for glomerular diseases represents one of the potentially first-in-class therapeutic opportunities that exist across Everest's broad pipeline and highlights our long-term growth strategy to advance innovative and high-quality therapies for the benefit of patients worldwide with unmet demand," said Zhengying Zhu, Ph.D., Chief Medical Officer for Internal Medicine at Everest Medicines. "Chronic kidney disease is a leading global public health problem and will remain as a top area of therapeutic focus for Everest Medicines. The initiation of this Phase 1b trial, alongside the pivotal-stage development of Nefecon, our lead asset in renal disease, strengthens the Company's commitment in this space and we look forward to progressing these important potential therapies as quickly as possible." About EVER001 EVER001 (previously known as XNW1011) is a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor in development globally for the treatment of renal diseases. BTK is an essential component of the B-cell receptor signaling pathways that regulate the survival, activation, proliferation, and differentiation of B lymphocytes. Targeting BTK with small molecule inhibitors has been demonstrated to be an effective treatment option for B-cell lymphomas and autoimmune diseases. Based in part on results from a completed phase 1 study with healthy subjects conducted by SinoMab in China, EVER001 exhibited high selectivity, excellent pharmacokinetics properties, robust target engagement and a safety profile that supports continued clinical development. Under an exclusive licensing agreement with Sinovent Pharmaceuticals and SinoMab BioScience, Everest owns the global rights to develop, produce and commercialize EVER001 for the treatment of renal diseases. About Everest Medicines Everest Medicines is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record of high-quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules, many of which are in late-stage clinical development. The Company's therapeutic areas of interest include oncology, autoimmune disorders, cardio-renal diseases and infectious diseases. For more information, please visit its website at www.everestmedicines.com.

Advancement highlights Everest's potential in providing first-in-class therapies to global patients with glomerular disease SHANGHAI, Sept. 25, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced today that the China National Medical Products Administration (NMPA)'s Center for Drug Evaluation has approved the Investigational New Drug (IND) application for a Phase 1b study of EVER001 (previously known as XNW1011), a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor, in development for the treatment of glomerular diseases. The planned Phase 1b clinical study will evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of EVER001 in patients in China with glomerular disease characterized by proteinuria, a common cause of chronic kidney disease. Under an exclusive licensing agreement with Sinovent Pharmaceuticals and SinoMab BioScience in September 2021, Everest owns the global rights to develop, produce and commercialize EVER001 for the treatment of renal diseases. Based on a Phase 1 study in healthy subjects in China conducted by SinoMab, EVER001 exhibited high selectivity, excellent pharmacokinetics properties and safety pro well as robust target engagement. "The advancement in clinical development of EVER001 for glomerular diseases represents one of the potentially first-in-class therapeutic opportunities that exist across Everest's broad pipeline and highlights our long-term growth strategy to advance innovative and high-quality therapies for the benefit of patients worldwide with unmet demand," said Zhengying Zhu, Ph.D., Chief Medical Officer for Internal Medicine at Everest Medicines. "Chronic kidney disease is a leading global public health problem and will remain as a top area of therapeutic focus for Everest Medicines. The initiation of this Phase 1b trial, alongside the pivotal-stage development of Nefecon, our lead asset in renal disease, strengthens the Company's commitment in this space and we look forward to progressing these important potential therapies as quickly as possible." About EVER001 EVER001 (previously known as XNW1011) is a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor in development globally for the treatment of renal diseases. BTK is an essential component of the B-cell receptor signaling pathways that regulate the survival, activation, proliferation, and differentiation of B lymphocytes. Targeting BTK with small molecule inhibitors has been demonstrated to be an effective treatment option for B-cell lymphomas and autoimmune diseases. Based in part on results from a completed phase 1 study with healthy subjects conducted by SinoMab in China, EVER001 exhibited high selectivity, excellent pharmacokinetics properties, robust target engagement and a safety pro supports continued clinical development. Under an exclusive licensing agreement with Sinovent Pharmaceuticals and SinoMab BioScience, Everest owns the global rights to develop, produce and commercialize EVER001 for the treatment of renal diseases. About Everest Medicines Everest Medicines is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record of high-quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules, many of which are in late-stage clinical development. The Company's therapeutic areas of interest include oncology, autoimmune disorders, cardio-renal diseases and infectious diseases. For more information, please visit its website at . Forward-Looking Statements: This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. View original content: SOURCE Everest Medicines Company Codes: HongKong:1952